This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Byrne, B. J. Articles by Gockerman, J. P. Search for Related Content PubMed PubMed Citation Articles by Byrne, B. J. Articles by Gockerman, J. P.

The Community Oncologist: Duke Oncology Fellows Series

Salvage Therapy in Hodgkin’s Lymphoma

Duke University Medical Center, Durham, North Carolina, USA

Correspondence: Brian J. Byrne, M.D., Duke University Medical Center, Box 3841, Durham, North Carolina, 27710 USA. Telephone: 919-684-2287; Fax: 919-684-3309; e-mail: byrne005{at}mc.duke.edu

Hodgkin’s disease is a rare malignancy that affects approximately 7,500 patients per year in the U.S., leading to an estimated 1,400 deaths. The relapse rate for this disease varies from around 5% for early-stage disease to 35% for patients with advanced disease. Patients who relapse after chemotherapy have about a 20% cure rate with conventional salvage chemotherapy. Two randomized phase III studies have shown an improved failure-free survival rate with high-dose chemotherapy and autologous stem cell support compared with conventional chemotherapy in relapsed patients. They failed to show any improvement in overall survival. For patients who experience failure with autologous transplant, the options of single-agent chemotherapy with gemcitabine, vinblastine, or vinorelbine can be used for palliation. Standard myeloablative allogeneic bone marrow transplant has a high mortality rate in this population. Allogeneic transplant regimens with reduced intensity are currently being studied in clinical trials. Further studies on the use of monoclonal antibodies and radiolabeled antibodies need to be conducted to define their role in the treatment of Hodgkin’s disease.